Novo real-world studies link Wegovy® 2.4 mg to reductions in liver enzymes, weight, and blood sugar in adults with MASH at The Liver Meeting® (AASLD) 2026
· prnewswire.com · popularity 16/100 · 0 similar stories today · Medicine & Clinical Health (Health & Life Sciences)
Read the original at prnewswire.com →
Summary
In a real-world study, semaglutide 2.4 mg once weekly injection was associated with a statistically significant mean weight loss from baseline, 18.9 lb (8.6 kg; ~8%), when compared to resmetirom at six months Semaglutide 2.4 mg was also associated with significantly greater reductions...
Found in: PR Newswire. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 16.